- The trend backdrop is active with a 27-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
VME
GER
Week ended 24 Jul 2026
Weekly Investor Report
Viromed Medical AG N · Healthcare · Medical Devices
Latest close
7.90 EUR
-0.6%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 26.5% above the Trend Line and sits at 90.6% of its 52-week range. The latest completed week returned -0.6%, after a 11.3% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 52/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.
Setup score
66
out of 100
Latest Close
7.90 EUR
24 Jul 2026
1W Return
-0.6%
latest completed week
4W Return
11.3%
short-term follow-through
12W Return
11.3%
quarterly tape
Trend Breadth
53.8%
28 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- 5 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.6%
Latest completed week; four-week move 11.3%.
Indicator stack
75/79
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
27 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 26.5% above the Trend Line and sits at 90.6% of its 52-week range. The latest completed week returned -0.6%, after a 11.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9812-week average 0.80
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.98Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers
No recent accumulation markers. 5 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 11.3% over four weeks, 11.3% over 12 weeks, and 127.0% over one year. The current trend has remained active for 27 consecutive weeks.
Performance by holding period
Active trend streak27 weeks
Active weeks in one year28
Trend breadth53.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.77Latest activity-pressure read.
Pressure change188.0%Four-week change in activity pressure.
Leadership48.80Latest relative-leadership reading.
RS change14.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 70%
Model confidence 57%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value17/100Relative valuation strength. Underlying universe rank 84; rank 1 is best.
Quality12/100Profitability and accounting quality. Underlying universe rank 89; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 277.7x Price divided by trailing earnings.
- Price / sales
- 33.0x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 44.9% Gross profit retained from each unit of revenue.
- Operating margin
- -17.0% Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -6.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 352.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 36.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 27 relevant articles.
3 positive · 24 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-6.5%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher11 of 2615 weeks finished lower.
Best week+26.2%Week of 30 Jan.
Worst week-15.5%Week of 13 Feb.
Latest week-0.6%Week of 24 Jul.
Shape of recent returns
Strong gains9
Modest gains2
Flat weeks0
Modest losses10
Sharp losses5
Recent vol5.8%13-week weekly-return volatility.
Base vol9.5%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew9.1% / -4.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank5 / 78
Group average1.5%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD64.1%positive activity pressure
RS43.6%positive relative leadership
Four-week leaders
IndustryDE Medical Devices
4-week rank3 / 12
Group average3.0%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD66.7%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape65/100
Trend, activity pressure, participation, and risk combine to a 65/100 tape read.
Indicator analysis73/100Latest 12-week confirmation: trend 12/12, activity pressure 6/12, relative leadership 12/12.
Activity pressure 0.98; 5 reversal markers Factors32/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 84; Small Cap Core rank 95 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 27 relevant articles.
Merit Medical Systems Inc (MMSI) (Q2 2026) Earnings Call Highlights: Strongest Organic Growth ... Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 7.90 EUR | -0.6% | 6.24 EUR | 4.59 EUR | 0.77 | 48.80 | 11.1K | On |
| 17 Jul 2026 | 7.95 EUR | 8.2% | 6.10 EUR | 4.55 EUR | 0.67 | 53.75 | 23.7K | On |
| 10 Jul 2026 | 7.35 EUR | 7.3% | 5.95 EUR | 4.51 EUR | 0.47 | 42.92 | 27.5K | On |
| 3 Jul 2026 | 6.85 EUR | -3.5% | 5.83 EUR | 4.47 EUR | 0.34 | 30.73 | 20.0K | On |
| 26 Jun 2026 | 7.10 EUR | 1.4% | 5.72 EUR | 4.44 EUR | 0.27 | 42.76 | 23.3K | On |
| 19 Jun 2026 | 7.00 EUR | -0.7% | 5.60 EUR | 4.40 EUR | 0.04 | 40.49 | 3.0K | On |
| 12 Jun 2026 | 7.05 EUR | -1.4% | 5.49 EUR | 4.36 EUR | -0.08 | 44.58 | 855 | On |
| 5 Jun 2026 | 7.15 EUR | 13.5% | 5.38 EUR | 4.33 EUR | -0.17 | 47.75 | 0 | On |
| 29 May 2026 | 6.30 EUR | -3.1% | 5.26 EUR | 4.29 EUR | -0.20 | 30.09 | 21.8K | On |
| 22 May 2026 | 6.50 EUR | -3.0% | 5.16 EUR | 4.26 EUR | -0.11 | 36.36 | 20.6K | On |
| 15 May 2026 | 6.70 EUR | -8.2% | 5.06 EUR | 4.23 EUR | -0.06 | 46.99 | 58.2K | On |
| 8 May 2026 | 7.30 EUR | 2.8% | 4.96 EUR | 4.19 EUR | -0.17 | 58.64 | 23.2K | On |
| 1 May 2026 | 7.10 EUR | 7.6% | 4.85 EUR | 4.14 EUR | -0.25 | 56.19 | 22.9K | On |
| 24 Apr 2026 | 6.60 EUR | 23.4% | 4.75 EUR | 4.10 EUR | -0.29 | 47.61 | 91.6K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.